WO2019227747A1 - 一种壳寡糖口服溶液及其制备方法 - Google Patents

一种壳寡糖口服溶液及其制备方法 Download PDF

Info

Publication number
WO2019227747A1
WO2019227747A1 PCT/CN2018/103514 CN2018103514W WO2019227747A1 WO 2019227747 A1 WO2019227747 A1 WO 2019227747A1 CN 2018103514 W CN2018103514 W CN 2018103514W WO 2019227747 A1 WO2019227747 A1 WO 2019227747A1
Authority
WO
WIPO (PCT)
Prior art keywords
chitosan
oral
parts
oral solution
chitooligosaccharide
Prior art date
Application number
PCT/CN2018/103514
Other languages
English (en)
French (fr)
Inventor
苏政权
Original Assignee
广东药科大学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 广东药科大学 filed Critical 广东药科大学
Publication of WO2019227747A1 publication Critical patent/WO2019227747A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Definitions

  • the invention relates to the field of pharmaceutical technology, in particular to an oral solution of chitooligosaccharide and a preparation method thereof.
  • Obesity is the most common metabolic imbalance disease. Obesity is becoming more and more common all over the world. This phenomenon not only occurs in Western society, but also occurs in developing countries as people become richer. Because obesity often induces high blood pressure, coronary heart disease, hyperlipidemia, fatty liver, cholecystitis, cholelithiasis, diabetes, impaired glucose tolerance, pulmonary insufficiency, obesity can weaken the body's resistance and make immune function Decline and abnormal blood rheology, triggering cerebral infarction, cerebral hemorrhage, myocardial infarction, respiratory diseases, deformable arthritis, varicose veins of lower limbs, women's amenorrhea, infertility, etc., have become public health issues of global concern.
  • Chitooligosaccharide also known as chitosan oligosaccharide, is an oligo-oligosaccharide formed by chitosan's main chain being broken by physical, chemical or enzymatic degradation. It is the only basic amino oligosaccharide with positive charge in nature.
  • the unique molecular structure of oligosaccharides has a variety of biological activities. Currently confirmed biological activities include lipid-lowering, enhancing immunity, anti-tumor, regulating blood lipids, regulating blood pressure, accelerating the absorption of calcium and iron in the body, reducing blood sugar, and Promote joint tissue repair and other functions.
  • chitooligosaccharide has become an emerging functional oligosaccharide in the world.
  • Chitooligosaccharide is an ideal biologically active substance, with good water solubility, small molecular weight, easy to absorb and use, and degradable, but chitosan has high hygroscopicity, which makes its preparation unstable.
  • dilute acid is used to dissolve chitosan, and then degraded into chitooligosaccharide at the optimum temperature of the biological enzyme, so the chitooligosaccharides have a slight acidity and have a bad taste.
  • the purpose of the present invention is to solve the technical problems of strong hygroscopicity, unstable preparation and poor taste in the prior art, and to provide a chitosan oral liquid preparation which obviously improves the stability of the chitosan liquid preparation and improves the taste Prescription process.
  • the invention also provides a method for preparing an oral liquid preparation of chitosan.
  • the auxiliary materials and processes used in the invention are convenient and available, and are suitable for industrial production.
  • the chito-oligosaccharide oral solution prepared by the invention has significant weight loss effect.
  • the oral liquid of the present invention is composed of the following components by weight:
  • chitooligosaccharide 25-40 parts of chitooligosaccharide, 1-3 parts of flavoring agent, 2-4 parts of preservative, 1.5-2 parts of stabilizer.
  • the flavoring agent is one or more of maltol or sodium carboxymethyl cellulose.
  • Maltol is a broad-spectrum high-efficiency flavor and sweetener with anti-bitter, deodorant and antiseptic effects. Gum substances such as sodium carboxymethyl cellulose can increase the viscosity of liquids and reduce the diffusion of drugs to taste buds in saliva. In the present invention, ethyl maltol and sodium carboxymethyl cellulose are selected as flavoring agents.
  • the flavoring agent is a mixture of ethyl maltol and sodium carboxymethyl cellulose, wherein the ratio of ethyl maltol to sodium carboxymethyl cellulose is 2: 1.
  • the preservative is one or more of potassium sorbate and sodium benzoate.
  • the stabilizer is one or more of xanthan gum, polyvinylpyrrolidone, sulfurous acid, and gallic acid.
  • Another object of the present invention is to provide a method for preparing an oral chitosan solution.
  • the method for preparing the oral solution includes the following steps: taking an appropriate amount of purified water, adding chitosan, a preservative, Stabilizer, shake in a constant temperature air bath until dissolution and inclusion are complete, then add a flavoring agent, and finally adjust the pH to 7.3.
  • the inventor also carried out an experiment on the weight loss effect of the chitosan oligosaccharide oral liquid of the present invention.
  • the experiment showed that the chitosan oligosaccharide oral liquid of the present invention has a significant weight loss effect, which is equivalent to the effect of the positive drug, and the chitosan oral liquid of the present invention is safe when used for weight loss High sex and small side effects.
  • the present invention has the following beneficial effects:
  • the invention can solve the problem of hygroscopicity of chitosan raw materials, and the prepared chitosan oral liquid is stable.
  • the present invention uses a specific combination of flavor modification formulas for chitooligosaccharides to mask the original bad taste of chitooligosaccharide oral solution and formulate a delicious taste.
  • the development of the chito-oligosaccharide liquid preparation of the present invention has greatly improved the compliance of patients with medication, and increased the population of users of the medication.
  • the oligochitosan liquid preparation of the present invention solves the process bottleneck of the dosage form of the drug, which is obtained by conventional liquid preparation processes, the preparation method is simple, the auxiliary materials used are readily available, and it is economical and suitable for industrial production.
  • Preparation method Take an appropriate amount of purified water, add chitosan, preservatives, and stabilizers according to the prescribed amount, shake in a constant temperature air bath until the dissolution and inclusion are complete, add flavoring agents, and finally adjust the pH to 7.3.
  • Preparation method Take an appropriate amount of purified water, add chitosan, preservatives, and stabilizers according to the prescribed amount, shake in a constant temperature air bath until the dissolution and inclusion are complete, add flavoring agents, and finally adjust the pH to 7.3.
  • Chitooligosaccharide 40g Ethyl maltol 0 Sodium carboxymethyl cellulose 2g Potassium sorbate 2g sodium benzoate 2g Xanthan Gum 0 Polyvinylpyrrolidone 1g Sulfurous acid 1g Gallic acid 0
  • Preparation method Take an appropriate amount of purified water, add chitosan, preservatives, and stabilizers according to the prescribed amount, shake in a constant temperature air bath until the dissolution and inclusion are complete, add flavoring agents, and finally adjust the pH to 7.3.
  • Preparation method Take an appropriate amount of purified water, add chitosan, preservatives, and stabilizers according to the prescribed amount, shake in a constant temperature air bath until the dissolution and inclusion are complete, then add flavoring agents, and finally adjust the pH to 7.3.
  • Preparation method Take an appropriate amount of purified water, add chitosan, preservatives, and stabilizers according to the prescribed amount, shake in a constant temperature air bath until the dissolution and inclusion are complete, add flavoring agents, and finally adjust the pH to 7.3.
  • Preparation method Take an appropriate amount of purified water, add chitosan, preservatives, and stabilizers according to the prescribed amount, shake in a constant temperature air bath until the dissolution and inclusion are complete, add flavoring agents, and finally adjust the pH to 7.3.
  • Oral liquids were prepared according to different prescription ratios, and were tasted by 40 volunteers. The scores were scored, the taste was described, and the combination of superior prescriptions was obtained through statistical results.
  • Scoring rules 0 points for tasteless taste; negative scores for bitterness, bad odor, and other negative scores, ranging from -1 to -10; sweet tastes, flavors, and other good tastes for positive scores, ranging from 1 to 10. The results are shown in Table 1:
  • Example 1 8.3 ⁇ 1.6
  • Example 2 6.9 ⁇ 1.2
  • Example 3 6.2 ⁇ 1.8
  • Example 4 7.5 ⁇ 2.1
  • Example 5 6.7 ⁇ 1.4
  • Example 6 6.5 ⁇ 1.7 Comparative Example 1 3.2 ⁇ 1.4
  • the oral liquid preparation of chitooligosaccharide of the present invention can mask the sour taste of chitooligosaccharide, and the taste is refreshing and delicious.
  • the chitosan oral liquid in the group of Example 1 had the best mouthfeel, indicating that the prescription component and the ratio were the best.
  • the inventor conducted a stability test of the chitosan oligosaccharide oral solution.
  • the chitosan oligosaccharide oral solution of Examples 1-6 was accelerated after 6 months and long-term stability inspection was conducted for 12 months. There were no significant changes in traits, identification, pH value, relative density, loading difference, content determination, and microbial limit inspection. The results showed that the quality of chitosan oral liquid was stable.
  • mice and males were randomly divided into a normal control group and a high-fat model group.
  • the normal control group was fed with ordinary feed, and the rest of the rats were fed with high-fat feed (basic feed + 30 lard) and fed for 4 months to induce obesity.
  • Obese rats were divided into obesity model group, orlistat group, and groups of Examples 1-6 according to body weight. They were administered orally at 20 ml / kg once a day for a total of 14 days. State, weigh the rats weekly.
  • the results are shown in Table 1. After 2 weeks of administration of the chitosan oral solution to obese rats, the weight of the rats was significantly reduced, and the difference was statistically significant compared with the model control group (P ⁇ 0.01).
  • the chitosan oligosaccharide oral solution in each of the groups of the examples was generally in good condition, with free movement, smooth hair, and no adverse reactions such as animal atrophy and loose stools were observed.
  • the chitosan oligosaccharide oral liquid has good lipid-lowering effect and high safety.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)

Abstract

本发明提供了一种壳寡糖口服液及其制备方法。所述的壳寡糖口服液包含壳寡糖25-40份，矫味剂1-3份、防腐剂2-4份、稳定剂1.5-2份。本发明的壳寡糖口服液明显改善壳寡糖液体制剂稳定性、改善壳寡糖的口感。本发明的壳寡糖口服液稳定性好，口感理想，并且减肥效果显著。

Description

一种壳寡糖口服溶液及其制备方法 技术领域
本发明涉及属于制药技术领域，具体涉及一种壳寡糖口服溶液及其制备方法。
背景技术
肥胖是最常见的代谢失衡性疾病，肥胖症在全世界愈来愈普遍，这种现象不仅发生在西方社会，而且，随着人们日益富裕起来，也发生在发展中国家。由于肥胖常诱发合并高血压，冠状动脉硬化性心脏病、高脂血症、脂肪肝、胆囊炎、胆石症、糖尿病、糖耐量异常、肺功能不全，肥胖并能削弱机体抵抗力，使免疫功能下降及血液流变异常，促发脑梗死、脑出血、心肌梗死、呼吸道疾病、变形性关节炎、下肢静脉曲张，妇女闭经、不孕等，从而成为全球普遍关注的公共健康问题。
由于肥胖可以导致严重的健康问题，因此肥胖症的防治也就成为医药学界进行研究的重要课题，虽然医学界普遍认为改善生活方式、合理饮食，加强运动是减肥的主要措施，但也认为对于过度肥胖患者经合理饮食、运动治疗未能达到满意控制者，可首选药物治疗。
现在很多复方中药制剂在广泛使用，但普遍存在着疗效不稳定，功效成份不明，难以在国际市场销售等问题。临床使用的各种化学减肥药，虽然有一定的疗效，但大多数有一定的副作用。
壳寡糖又称几丁寡糖，是壳聚糖经物理、化学或酶降解等方式将其主链断裂后形成的低聚寡糖，是自然界中唯一含有正电荷的碱性氨基寡糖。聚寡糖独特的分子结构使其具有多种生物活性，目前已经被确认的生物活性包括降脂、增强免疫力、抗肿瘤、调节血脂、调节血压、加速体内钙和铁的吸收、降低血糖以及促进关节组织的修复等功能。目前壳寡糖已经一种成为国际上新兴功能性低聚糖。
壳寡糖是极理想的生物活性物质，水溶性好，分子量小，容易吸收利用及可降解，但是壳寡糖吸湿性强，导致其制剂不稳定。由于壳寡糖生产过程中，采用稀酸溶解壳聚糖，然后在生物酶最适温度下降解成壳寡糖，所以壳寡糖都带有些许酸味，口感不好。
因此，研制一种新的壳寡糖剂型，解决其吸湿性强、制剂不稳定、口感差的技术问题，以充分发挥其减肥功效，具有重要意义。
发明内容
本发明的目的是针对现有技术中壳寡糖吸湿性强，制剂不稳定以及口感差的技术问题， 提供一种明显改善壳寡糖液体制剂稳定性、改善口感的壳寡糖口服液体制剂的处方工艺。本发明还提供一种壳寡糖口服液体制剂的制备方法。
本发明使用的辅料和工艺方便可得，适用于工业化生产。本发明制得的壳寡糖口服液减肥效果显著。
本发明通过以下技术方案实现：
本发明口服液由下列组份按重量份组成：
壳寡糖25-40份，矫味剂1-3份、防腐剂2-4份、稳定剂1.5-2份。
所述的矫味剂为麦芽酚或羧甲基纤维素钠中的一种或多种。
麦芽酚具有抑苦、去腥臭及防腐等作用，是一种广谱高效增香剂和增甜剂。羧甲基纤维素钠等胶类物质可增加液体黏度，降低药物在唾液中向味蕾的扩散。本发明选择乙基麦芽酚、羧甲基纤维素钠为矫味剂。
进一步地，所述矫味剂为乙基麦芽酚和羧甲基纤维素钠的混合，其中乙基麦芽酚与羧甲基纤维素钠的比例为2:1。
进一步地，所述防腐剂为山梨酸钾和苯甲酸钠的一种或多种。
进一步地，所述稳定剂为黄原胶、聚乙烯基吡咯烷酮、亚硫酸和没食子酸中的一种或多种。
本发明的另一目的在于提供一种壳寡糖口服液的制备方法，具体地，所述口服液的制备方法，包括以下步骤：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
发明人进行了壳寡糖口服液的稳定性试验，加速试验和长期稳定性试验考察表明，本发明壳寡糖口服液在性状、鉴别、PH值、相对密度、装量差异、含量测定、微生物限度检查等方面都无明显变化。本发明壳寡糖口服液样品质量稳定。
发明人还进行了本发明壳寡糖口服液的减肥效果实验，实验表明本发明的壳寡糖口服液减肥效果显著，与阳性药效果相当，并且本发明壳寡糖口服液用于减肥时安全性高、副作用小。
与现有技术相比，本发明具有以下有益效果：
1.本发明可解决壳寡糖原料的吸湿性问题，制得的壳寡糖口服液稳定。
2.本发明通过对壳寡糖利用特定组合的矫味配方，将壳寡糖口服液原有的不良味道掩盖，并调配出可口的口感。
3.本发明的壳寡糖液体制剂的开发大大提高患者用药的顺应性，增加了该药物的使用人 群。
4.本发明的壳寡糖液体制剂解决该药物该剂型的工艺瓶颈，采用常规液体制备工艺制备可得，制备方法简便，使用的辅料易得，经济，适用于工业化生产。
具体实施方式
通过以下实例来对本发明做进一步具体说明，包括但并不仅仅限于以下实例。
实施例1壳寡糖口服溶液
处方：
壳寡糖 25g
乙基麦芽酚 2g
羧甲基纤维素钠 1g
山梨酸钾 2g
苯甲酸钠 0
黄原胶 0.5g
聚乙烯基吡咯烷酮 1g
亚硫酸 0
没食子酸 0
制备方法：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
实施例2壳寡糖口服溶液
处方：
壳寡糖 30g
乙基麦芽酚 2g
羧甲基纤维素钠 0
山梨酸钾 0
苯甲酸钠 4g
黄原胶 2g
聚乙烯基吡咯烷酮 0
亚硫酸 0
没食子酸 0
制备方法：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
实施例3壳寡糖口服溶液
处方：
壳寡糖 40g
乙基麦芽酚 0
羧甲基纤维素钠 2g
山梨酸钾 2g
苯甲酸钠 2g
黄原胶 0
聚乙烯基吡咯烷酮 1g
亚硫酸 1g
没食子酸 0
制备方法：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
实施例4壳寡糖口服溶液
处方：
壳寡糖 32g
乙基麦芽酚 1g
羧甲基纤维素钠 1g
山梨酸钾 1g
苯甲酸钠 2g
黄原胶 0
聚乙烯基吡咯烷酮 1.5g
亚硫酸 0
没食子酸 0.5g
制备方法：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振 摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
实施例5壳寡糖口服溶液
处方：
壳寡糖 38g
乙基麦芽酚 1g
羧甲基纤维素钠 0
山梨酸钾 3g
苯甲酸钠 1g
黄原胶 0.5g
聚乙烯基吡咯烷酮 1g
亚硫酸 0
没食子酸 0
制备方法：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
实施例6壳寡糖口服溶液
处方：
壳寡糖 26g
乙基麦芽酚 0
羧甲基纤维素钠 3g
山梨酸钾 0
苯甲酸钠 3g
黄原胶 0
聚乙烯基吡咯烷酮 2g
亚硫酸 0
没食子酸 0
制备方法：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
对比例1
壳寡糖 25g
阿斯巴甜 2g
安赛蜜 1g
山梨酸钾 2g
苯甲酸钠 0
黄原胶 0.5g
聚乙烯基吡咯烷酮 1g
亚硫酸 0
没食子酸 0
制备方法同实施例1。
实施例7壳寡糖口服液体制剂矫味实验
方法：按不同处方比例调配口服液，通过40名志愿者品尝，对各处方进行打分，叙述口感，统计结果得出较优处方的组合。
打分细则：无味为0分；苦味，不良气味等负面口感打负分，范围在-1～-10；甜味，香味等可口的口感打正分，范围在1～10。结果如表1：
表1壳寡糖液体制剂矫味实验
  甜味评分
实施例1 8.3±1.6
实施例2 6.9±1.2
实施例3 6.2±1.8
实施例4 7.5±2.1
实施例5 6.7±1.4
实施例6 6.5±1.7
对比例1 3.2±1.4
本发明的壳寡糖口服液体制剂能将壳寡糖的酸味掩盖，且口感清爽可口。尤其是实施例1组的壳寡糖口服液口感最好，说明该处方组分和配比最佳。
对比例1组处方中虽然阿斯巴甜和安赛蜜口感甜，但同时引入了其他怪味，有如金属、塑料的味道，口感不理想。
实施例8本发明壳寡糖稳定性试验
发明人进行了壳寡糖口服液的稳定性试验，将实施例1-6的壳寡糖口服液，经过6个月加速、12个月长期稳定性考察，考核项目指标与0月比较，在性状、鉴别、PH值、相对密度、装量差异、含量测定、微生物限度检查等方面都无明显变化。表明壳寡糖口服液样品质量稳定。
实施例9壳寡糖口服液减肥降脂实验研究
取SD大鼠，雄性，随机分为正常对照组和高脂模型组，正常对照组饲喂普通饲料，其余大鼠给予高脂饲料(基础饲料+30猪油)，连续饲养4个月诱导肥胖大鼠，将肥胖大鼠依体重分为肥胖模型组、奥利司他组、实施例1-6各组，按20ml/kg灌胃给药，一天一次，共14天，每天观察大鼠的状态，每周称量大鼠体重。
结果如表1指出：给予肥胖大鼠壳寡糖口服液2周后，大鼠体重显著减轻，与模型对照组比较差异有统计学意义(P<0.01)。壳寡糖口服液各实施例组别大鼠的一般情况良好，活动自如，毛发顺滑，未观察到动物精神萎靡、稀便等不良反应。本发明壳寡糖口服液降脂效果想良好，安全性高。
表1壳寡糖口服液对高脂饮食诱导肥胖大鼠体重的影响
Figure PCTCN2018103514-appb-000001
与模型对照组比较，*P<0.05,**P<0.01。

Claims (6)

  1. 一种壳寡糖口服液，其特征在于，所述口服液包含如下重量配比的原辅料：
    壳寡糖25-40份，矫味剂1-3份、防腐剂2-4份、稳定剂1.5-2份。
  2. 如权利要求1所述的壳寡糖口服液，其特征在于，所述的矫味剂为麦芽酚或羧甲基纤维素钠中的一种或多种。
  3. 如权利要求1或2所述的壳寡糖口服液，其特征在于，所述矫味剂为乙基麦芽酚和羧甲基纤维素钠的混合，其中乙基麦芽酚与羧甲基纤维素钠的比例为2:1。
  4. 如权利要求1所述的壳寡糖口服液，其特征在于，所述防腐剂为山梨酸钾和苯甲酸钠的一种或多种。
  5. 如权利要求1所述的壳寡糖口服液，其特征在于，所述稳定剂为黄原胶、聚乙烯基吡咯烷酮、亚硫酸和没食子酸中的一种或多种。
  6. 如权利要求1～5任一所述的壳寡糖口服液的制备方法，其特征在于，包含以下步骤：取纯化水适量，按处方量加入壳寡糖、防腐剂、稳定剂，在恒温空气浴中振摇至溶解包合完全，再加入矫味剂，最后调节pH至7.3，即可。
PCT/CN2018/103514 2018-06-01 2018-08-31 一种壳寡糖口服溶液及其制备方法 WO2019227747A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201810554058.9A CN108653317B (zh) 2018-06-01 2018-06-01 一种壳寡糖口服溶液及其制备方法
CN201810554058.9 2018-06-01

Publications (1)

Publication Number Publication Date
WO2019227747A1 true WO2019227747A1 (zh) 2019-12-05

Family

ID=63774370

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2018/103514 WO2019227747A1 (zh) 2018-06-01 2018-08-31 一种壳寡糖口服溶液及其制备方法

Country Status (2)

Country Link
CN (1) CN108653317B (zh)
WO (1) WO2019227747A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111617030B (zh) * 2020-05-22 2021-09-07 广东药科大学 壳寡糖口服液及其在制备减肥药物中的应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602891A (zh) * 2004-07-27 2005-04-06 张英伟 低聚壳聚糖口服液
CN106617024A (zh) * 2016-10-17 2017-05-10 广东省阳春市信德生物科技发展有限公司 一种黑蒜壳寡糖口服液配方及其制备工艺

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105533387A (zh) * 2015-12-09 2016-05-04 山东凯尔海洋生物科技有限公司 一种含有菊粉和壳寡糖的固体饮料及其制备方法
CN106962613A (zh) * 2017-03-15 2017-07-21 成都合生元生物科技有限公司 一种寡聚糖组合物及其制备方法和饲料

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1602891A (zh) * 2004-07-27 2005-04-06 张英伟 低聚壳聚糖口服液
CN106617024A (zh) * 2016-10-17 2017-05-10 广东省阳春市信德生物科技发展有限公司 一种黑蒜壳寡糖口服液配方及其制备工艺

Also Published As

Publication number Publication date
CN108653317B (zh) 2021-04-06
CN108653317A (zh) 2018-10-16

Similar Documents

Publication Publication Date Title
CA2822683C (en) Bepotastine compositions
TW501930B (en) Pharmaceutical, orally applicable composition with antacid active substance
AU2007298814B2 (en) Galenic form for the trans-mucosal delivery of active ingredients
JP2021508670A (ja) 疾患の処置のための鼻腔内エピネフリン製剤及び方法
WO2007046347A1 (ja) 筋萎縮性側索硬化症患者の運動神経保護用医薬
TWI342773B (zh)
KR101490721B1 (ko) 감칠맛을 가진 디페리프론용 액상 제제
EP0379753B1 (de) N-Acetylglucosamin-Zubereitungen zur buccalen Anwendung
JPWO2006001344A1 (ja) イソソルビド含有ゼリー製剤
WO2019227747A1 (zh) 一种壳寡糖口服溶液及其制备方法
US20100113453A1 (en) Sublingual Formulations of D-Cycloserine and Methods of Using Same
US20200390691A1 (en) Compositions, devices, and methods for the treatment of overdose and reward-based disorders
KR100927254B1 (ko) 분지쇄 아미노산을 포함하는 액상 조성물 및 이의 제조방법
JP2008094743A (ja) 摂食・嚥下改善食品
US20070053939A1 (en) Biguanide drug-containing jelly preparation
JP4959864B2 (ja) グルタミン酸塩含有液剤
US10245278B2 (en) Liquid or semi-liquid pharmaceutical, dietary or food composition free of bitterness containing an arginine salt
JP6840647B2 (ja) 液体組成物、その白濁改善剤、臭気改善剤、及び製造方法
JP2022514340A (ja) 過剰摂取および報酬に基づく障害を処置するための、組成物、装置、および方法
JP2003342186A (ja) 鼻炎用内服液剤組成物
KR101458670B1 (ko) 분지쇄아미노산을 함유하는 약제학적 조성물 및 그 제조방법
US11058138B2 (en) Composition for calcium supplementation
EP3678498B1 (en) Composition for calcium supplementation
JP7291380B2 (ja) 鼻水又は鼻づまりの口腔粘膜投与用即効性改善剤
JPS63313725A (ja) シロツプ剤

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18920662

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18920662

Country of ref document: EP

Kind code of ref document: A1